ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 227 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104,504 | -32.8% | 19,175 | -17.3% | 0.00% | – |
| Q2 2023 | $155,551 | -29.7% | 23,182 | -7.5% | 0.00% | – |
| Q1 2023 | $221,209 | +29.3% | 25,052 | +11.8% | 0.00% | – |
| Q4 2022 | $171,144 | -2.8% | 22,401 | -9.4% | 0.00% | – |
| Q3 2022 | $176,000 | -17.4% | 24,721 | -6.0% | 0.00% | – |
| Q2 2022 | $213,000 | -17.1% | 26,299 | +42.0% | 0.00% | – |
| Q1 2022 | $257,000 | -80.2% | 18,521 | -59.9% | 0.00% | -100.0% |
| Q4 2021 | $1,297,000 | -15.6% | 46,206 | +2.2% | 0.00% | 0.0% |
| Q3 2021 | $1,537,000 | -16.5% | 45,221 | +0.4% | 0.00% | 0.0% |
| Q2 2021 | $1,841,000 | +5.5% | 45,057 | +3.9% | 0.00% | 0.0% |
| Q1 2021 | $1,745,000 | -2.8% | 43,350 | +42.7% | 0.00% | 0.0% |
| Q4 2020 | $1,796,000 | +82.5% | 30,378 | +50.1% | 0.00% | 0.0% |
| Q3 2020 | $984,000 | +137.1% | 20,233 | +135.9% | 0.00% | – |
| Q2 2020 | $415,000 | – | 8,577 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |